Comparative Pharmacology
Head-to-head clinical analysis: AMIDATE versus ETOMIDATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMIDATE versus ETOMIDATE.
AMIDATE vs ETOMIDATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AMIDATE (etomidate) is a nonbarbiturate hypnotic agent that acts as a positive allosteric modulator of the GABA-A receptor at the beta-2/3 subunit, enhancing the inhibitory effects of GABA and producing rapid sedation and anesthesia.
Etomidate is a nonbarbiturate hypnotic agent that acts as a positive allosteric modulator of the gamma-aminobutyric acid (GABA) type A receptor, enhancing GABA-mediated inhibition in the central nervous system. It produces rapid anesthesia with minimal cardiovascular and respiratory depression.
0.2-0.6 mg/kg IV bolus for induction of anesthesia.
Induction: 0.2–0.6 mg/kg IV over 30–60 seconds. Maintenance: 10–20 mcg/kg/min IV continuous infusion.
None Documented
None Documented
Clinical Note
moderateEtomidate + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Etomidate is combined with Fluticasone propionate."
Clinical Note
moderateEtomidate + Clemastine
"The risk or severity of adverse effects can be increased when Etomidate is combined with Clemastine."
Clinical Note
moderateEtomidate + Venlafaxine
"Etomidate may decrease the antihypertensive activities of Venlafaxine."
Clinical Note
moderateEtomidate + Nefazodone
Terminal elimination half-life: 2.5–4 hours (adults); 1–2 hours (children); Prolonged in hepatic impairment or with continuous infusion.
Terminal elimination half-life: 2.9–5.3 hours (context: redistribution shortens clinical effect; hepatic impairment prolongs).
Renal: <5% unchanged; Hepatic metabolism to carboxylic acid metabolite (inactive); Metabolite renally eliminated; Fecal: negligible.
Renal: 75% as metabolite (carboxylic acid), 2% unchanged; fecal/biliary: minimal.
Category C
Category C
General Anesthetic
General Anesthetic
"The risk or severity of adverse effects can be increased when Etomidate is combined with Nefazodone."